What is TrumpRx? Deal with Eli Lilly, Novo Nordisk, Medicare on weight loss drug coverage

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Novo: The Double Bottom Is In

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

Analysis-Novo Nordisk CEO signals new appetite for risk in obesity deals

By Sabrina Valle and Maggie Fick NEW YORK/LONDON (Reuters) -When Novo Nordisk CEO Mike Doustdar learned in late September ...

What’s Next for Novo Nordisk?

After [losing out to Pfizer]( ...
WISH-TV

Novo Nordisk, Eli Lilly deny partnership with Mangoceuticals on weight-loss drugs

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk: Problems Compound, But Stock Still Cheap (Rating Downgrade)

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market ...
BioSpace

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...
Labiotech.eu

Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...